Course: Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
CME Credits: 1.00
Released: 2021-08-11
The effectiveness of COVID-19 vaccination remains unknown in patients with hematologic malignant disease who have an impaired humoral immunity from both treatment and disease. Phase 3 registration studies of COVID-19 vaccines excluded patients with immunosuppression or immunosuppressive therapies., Despite this, professional organizations suggest vaccination, or even its prioritization, for patients with cancer. As the US Centers for Disease Control loosens pandemic-related precautions for vaccinated people, a better understanding of the vaccine response among patients with hematologic malignant disease is critical.
Educational Objective
To identify the key insights or developments described in this article
View Full Course